Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 22 months.
- Instrument
- loan
- Principal
- $11,005,000
- Counterparty
- Streeterville Capital, LLC
- Rate
- 8% per annum
- Maturity
- 22 months
- Event
- incurrence
Exact text from the filing
On March 2, 2023, Northwest Biotherapeutics, Inc. (the "Company") entered into a Commercial Loan Agreement and Note (collectively, the "Loan Agreement") with Streeterville Capital, LLC (the "Holder") in the amount of $11,005,000.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NORTHWEST BIOTHERAPEUTICS INC entered into Loan Agreement with Streeterville Capital, LLC valued at $11,005,000 (effective 2023-03-02).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Streeterville Capital, LLC
- Value
- $11,005,000
- Effective
- 2023-03-02
Exact text from the filing
On March 2, 2023, Northwest Biotherapeutics, Inc. (the "Company") entered into a Commercial Loan Agreement and Note (collectively, the "Loan Agreement") with Streeterville Capital, LLC (the "Holder") in the amount of $11,005,000.
View on SEC.gov